Vitamin D and vitamin D receptor in patients with ophthalmic pterygium

Cristina Maxia, Daniela Murtas, Michela Corras, Ignazio Zucca, Luigi Minerba, Franca Piras, Cristina Marinelli, Maria Teresa Perra

1Department of Biomedical Sciences, University of Cagliari
2Department of Surgical Science, Eye Clinic, University of Cagliari
3Department of Public Health, Clinical and Molecular Medicine, University of Cagliari
4Laboratory of Clinical Chemistry, Hematology and Microbiology, Hospital G. Brotzu, Cagliari, Italy

Abstract

Pterygium, an ultraviolet radiation (UV)-related disease, is a relatively benign process, but since it displaces tumor-like features, it has been proposed to be a neoplastic-like growth disorder. Vitamin D performs a number of functions in addition to calcium homeostasis, as inhibition of cell proliferation, activation of apoptotic pathways, and inhibition of angiogenesis. Since the antitumor actions of vitamin D are mediated primarily through the nuclear vitamin D receptor (VDR), the aim of the present study was to investigate vitamin D status in patients with pterygium and in control subjects, and VDR immunohistochemical expression in samples of pterygium and normal conjunctiva in order to evaluate a possible role of vitamin D in the pathogenesis of the disease. Serum vitamin D concentration was measured among 41 patients with pterygium and 47 volunteers by an automated chemiluminiscence assay. Moreover, 23 formalin-fixed and paraffin-embedded pterygium biopsy samples and 24 conjunctiva specimens were treated for the immunohistochemical demonstration of VDR using the streptavidin-biotin alkaline phosphatase method. No differences were observed about vitamin D level between patient with pterygium and control group, but significant differences between VDR immunolocalization in pterygium and normal conjunctiva were observed (P<0.00001). In conjunctiva, the immunoreactivity, localized mainly in cytoplasm of epithelial cells, may probably demonstrate VDR regulation of cell growth, differentiation, and apoptosis, while in pterygium VDR co-localization in the nucleus and cytoplasm of epithelial cells may indicate alternative nuclear pathways by which vitamin D might exert its anti-inflammatory and anti-proliferative effects by the regulation of gene expression.

Introduction

Pterygium is a chronic condition characterized by the encroachment of altered bulbar conjunctiva into the normal cornea. Histologically it consists of a superficial conjunctival epithelial layer and an underlying fibrovascular component, with features indicative of both degenerative process and disordered growth. Pterygium is a relatively benign process, but since it displays tumor-like features, as aggressive recurrence after removal and local invasiveness with various degrees of abnormalities, ranging from mild dysplasia to carcinoma in situ, it has been proposed to be a neoplastic-like growth disorder. As a matter of fact, several authors demonstrated that neoplastic lesions may be associated with pterygium. Many factors have been proposed as causative agents in its pathogenesis, such as extracellular matrix remodelling, inflammatory process, anti-apoptotic mechanisms, cytokines, growth and angiogenic factors, viral infection, oxidative stress, hypoxic ischemic injury, anomaly in epithelial differentiation and wound healing defect. However, it is well-established that pterygium is an ultraviolet radiation (UV)-related disease. For a long time several authors have labelled pterygium as a chronic degenerative growth disorder, but, following the discovery of p53 overexpression in the epithelium, it is now considered as an UV-related tumor. Although its pathogenesis seems multi-factorial, chronic inflammation, angiogenesis and uncontrolled proliferation have a key role in the pathogenesis of pterygium.

Besides being taken up exogenously through dietary intake, when the skin is exposed to solar or artificial UV-B light, humans obtain endogenously a fat-soluble vitamin called vitamin D. The biologically active form of vitamin D, 1,25-dihydroxyvitamin D, also known as calcitriol, plays its major physiological role in maintaining mineral ion homeostasis and regulating intestinal calcium absorption. In addition to its well documented role, the scientific community has focused attention in the relationship between low serum vitamin D levels and a variety of seemingly disparate systemic conditions, including multiple sclerosis, cardiovascular disease, schizophrenia, type 1 diabetes mellitus, and infections, particularly tuberculosis and influenza.

More recently, vitamin D status has been inversely associated with risk for various cancers, since vitamin D inhibits cell...
proliferation pathways, activates apoptotic pathways, and exerts pro-differentiative effects.\textsuperscript{39,40} In 1980, Garland and Garland\textsuperscript{41} reported an inverse association between basal vitamin D exposure and colon cancer mortality, hypothesizing for vitamin D a protective role against the risk of colon cancer. To support these evidences, epidemiological studies have shown an association between low circulating 25-hydroxyvitamin D3 [25 OH Vitamin D; 25(OH)D] levels, a biomarker of vitamin D exposure, and increased risk for colorectal, breast and prostate cancers.\textsuperscript{38-40}

The action of vitamin D is mediated by the nuclear vitamin D receptor (VDR), a 48 to 55 kD activated transcription factor, expressed in various tissues, including those not involved in mineral metabolism.\textsuperscript{41} VDR is expressed by normal and neoplastic cells, and it is localized mostly in the nucleus although some authors have also reported cytoplasmic receptors.\textsuperscript{42,43} It is well-established that the lack of the active hormonal form of vitamin D or its nuclear receptor results in the development of hypocalcemia and its related clinical manifestations.\textsuperscript{34,35}

Since the antitumor actions of vitamin D are mediated primarily through VDR, and little is known about this subject in pterygium, the aim of the present study was to investigate vitamin D status in patients with pterygium and in control subjects, and VDR immunohistochemical expression in biopic samples of pterygium and normal conjunctiva; the knowledge of vitamin D status and VDR localization may contribute to the understanding of the pathogenesis of the disease.

Materials and Methods

Vitamin D status: Patients and study design

We conducted the study on vitamin D status among 41 adults (30 males and 11 females) (age 28-82 years; mean 58.34±15.08) that were admitted and treated for primary pterygium excision by bare sclera technique at the Department of Surgical Science, Eye Clinic, University of Cagliari (Sardinia, Italy), during summer 2012 and 2013. During the same periods, 47 volunteer healthy subjects (13 males and 34 females) (age 25-66 years; mean 43.74±11.74) were considered eligible as normal control subjects for this study. They were recruited among the Eye Clinic staff, their family and friends. They should not have history of pterygium and/or other ocular surface diseases. Both patients and volunteers did not receive any vitamin D dietary supplement in the 6 months before the analysis, and no one reported history of pathologies related to vitamin D deficiency, such as fat malabsorption, liver disease or renal insufficiency. In Table 1 are reported the characteristics of patients selected for the evaluation of serum vitamin D concentration.

The study protocol was approved by the local Institutional Research Ethic Committee. Written informed consent was obtained from all participants prior to the initiation of the study.

Concentration of 25(OH)D in both patients and volunteers was determined at the Laboratory of Clinical Chemistry, Hematology and Microbiology, Hospital “G. Brotzu”, Cagliari, by the LIAISON® 25 OH vitamin D assay, a direct, competitive chemiluminescent immunoassay (CLIA) for quantitative determination of total 25 OH vitamin D in serum or plasma (DiaSorin LIAISON®, Stillwater, MN, USA), following the experimental protocol optimized by DiaSorin Inc.\textsuperscript{46} “During the first incubation, 25 OH vitamin D is dissociated from its binding protein and binds to the specific antibody on the solid phase. After 10 min the tracer (vitamin D linked to an isoluminol derivative) is added. After an additional 10 min incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents are added to initiate a flash chemiluminescent reaction. The light signal is measured by a photomultiplier as relative light units (RLU) and is inversely proportional to the concentration of 25 OH vitamin D present in calibrators, controls, or samples.”

The scientific community recommends the following ranges for the classification of 25-OH vitamin D status, as reported in DiaSorin LIAISON® datasheet: deficiency, with 25(OH)D plasma concentration <10 ng/mL (level 1); insufficiency, between 10-30 ng/mL (level 2); sufficiency, between 30-100 ng/mL (level 3) and toxicity, with 25(OH)D level >100 ng/mL (level 4).

VDR immunohistochemistry: Patients and study design

Among the group of 41 patients admitted and treated for primary pterygium excision, only 23 specimens were processed for paraffin embedding; moreover, 24 exposed bulbar conjunctiva biopsy samples, collected from patients without pterygium (non-pterygium subjects), who underwent cataract and strabismus surgery at the Eye Clinic, were formalin-fixed and paraffin embedded and used as normal controls. Most of pterygium were located on the nasal side and only the head of the lesion was used as biopic sample. The study included 16 inflamed and 7 quiescent lesions, and pterygium morphology was clinically graded as atrophic (6 cases), intermediate (13 cases), or fleshy (4 cases) according to an assessment of pterygium translucency. In both groups, the vitamin D status was assessed. Patients did not receive any medication before surgery except for a topical anaesthetic, and no drugs or chemical agents were used during surgical operation. Complete demographic and clinical information on patients was available in all cases (Table 2).

Microtome histological sections (6-7 μm thick) were treated for the immunohistochemical demonstration of VDR using the streptavidin-biotin alkaline phosphatase method. They were dewaxed in xylene and rehydrated in a graded alcohol series and phosphate-buffered saline (PBS). Water
bath heating-based antigen retrieval was performed by immersion in 10 mM citrate buffer solution (pH 6.0) at 95°C for 30 min. After gradual cooling for 20 min, sections were treated for 45 min with 10% normal goat serum in PBS. Mouse monoclonal antibody (1:1000, clone D6, Santa Cruz Biotechnology Inc., Dallas, TX, USA) to human VDR, raised against amino acids 344-424, which possesses the highest specificity, sensitivity, and versatility, was used as primary antiserum and incubated overnight at 4°C. Biotinylated anti-mouse IgG was used as secondary antiserum (1:800; Vector Laboratories, Burlingame, CA, USA) and incubated for 30 min at room temperature; the sections were further incubated in alkaline phosphatase streptavidin (1:1000; Vector Laboratories) for 30 min at room temperature and reacted with Fast Red Substrate System (Dako, Glostrup, Denmark). All sections were thoroughly rinsed in PBS between each step, and finally counterstained with Mayer hematoxylin and mounted in glycerol gelatin (Sigma, St. Louis, MO, USA).

Sections of an archival biopsy specimen of prostate were used as positive control tissue; negative controls were obtained by omission of the primary antibody or by replacing the primary antibody with an isotype-matched antibody. Positive and negative controls were run simultaneously.

Micrographs were captured by a Lumenera’s INFINITY 3-1 digital camera on a microscope Zeiss Axiophot (Carl Zeiss Inc., Oberkochen, Germany), and processed by Adobe Photoshop (ver. 7.0; Adobe Systems, Inc., San Jose, CA, USA) software.

Evaluation of immunoreactivity

Results were independently evaluated by three observers (CM, DM, MTP) in a blinded fashion, as described in our previous paper. Four to six 200× fields covering almost the whole of each of the four sections per sample were examined with a 144-intersection point square reticulum (0.78 mm²) inserted in the eyepiece and scored for the percentage of epithelial immunoreactive cells. In each sample, it was evaluated if the staining was localized only in nucleus, only in cytoplasm or both in nucleus and cytoplasm of epithelial cells. The intensity of VDR staining was graded 0, 1+, 2+, 3+. The VDR protein was considered to be highly expressed if 10% or more of the cells stained with an intensity score of 2+ or 3+, as described in 2014 by Zhou et al. in esophageal adenocarcinoma and precancerous lesions.

Statistical analysis

The results of the evaluation of 25(OH)D plasma mean concentration and of the VDR immunohistochemical analysis were analyzed by Student’s t-test and Fisher’s exact test, respectively. Data were computed by the IBM® SPSS® Statistics 21.0. The tests used were two-tailed. A P value ≤0.05 was considered statistically significant.

Results

Vitamin D status

Among the 41 patients with pterygium and the 47 healthy subjects of the control group, the mean concentration of plasma 25(OH)D was 19.47 ng/mL ±7.37 (median 18.7 ng/mL, range 5.82-35.4 ng/mL) and 18.22 ng/mL ±8.01 (median 15.8 ng/mL, range 7.92-45.2 ng/mL) respectively (Table 1). Among pterygium patients, only 5 people (12%) had level 3 concentration, while 32 patients had level 2 (78%) and 4 subjects had level 1 (10%). No patients showed toxic concentrations of vitamin D (Table 3). Regarding the 25(OH)D plasma mean concentration, no statistical differences between pterygium and control group were observed, as assessed by Student’s t-test (P>0.05).

VDR immunohistochemistry

Immunohistochemical analysis of VDR expression in the 23 pterygium specimens showed a moderate to strong immunoreactivity of the epithelial cells, being localized in both nucleus and cytoplasm (Figure 1A) in 19 samples (83%), while in 3 samples (13%) the immunostaining was detected only in cytoplasm (Table 4). One specimen (4%) did not show any immunoreactivity. No specimens showed exclusively nuclear staining. In the reactive samples, the nuclear staining was always stronger than the cytoplasmic. In most samples, a marked VDR immunostaining was also detected in epithelial goblet cells (Figure 1A) and in the endothelial cells of sub-epithelial microvessels (Figure 1A.C). Scattered immunoreactive leucocytes-like cells, morphologically...
recognizable as cells belonging to the “mononuclear phagocyte system (MPS)”, were found in the subepithelial connective tissue (Figure 1C) and inside the vessels (Figure 1D). The mean concentration of 25(OH)D in patients with pterygium was 22.09 ng/mL ±7.17 (median 20.7 ng/mL, range 11.8-35.4 ng/mL) (Table 2). Among the normal conjunctival samples, 16 (67%) exhibited mainly a cytoplasmic staining for VDR (Figure 1B) in the epithelial cells, while only 2 samples (8%) displayed both nuclear and cytoplasmic immunoreaction (Table 4); six specimens (25%) showed no immunostaining. The mean concentration of 25(OH)D in these patients was 22.06 ng/mL ±8.28 (median 21.7 ng/mL, range 7.4-34.9 ng/mL) (Table 2).

The Vitamin D concentration detected in the non-pterygium subjects was comparable to that of the healthy subjects. Most conjunctivas displayed mainly mild to moderate staining, while in pterygium the immunoreaction was always more intense. In the negative control sections the immunoreactivity was completely abolished (Figure 1F).

Regardless of vitamin D status (P>0.05), significant differences between VDR immunohistochemical localization in pterygium and normal conjunctiva were noticed, as assessed by Fisher’s exact test (P=0.00001) (Table 4). Moreover, in pterygium no correlation between VDR expression and demographic or clinical parameters (age, gender, location, disease stage and grade) was observed (P>0.05).

Table 4. Immunohistochemical localization of vitamin D receptor in pterygium and normal conjunctiva.

| Localization                  | Pterygium (positive/total) | Conjunctiva (positive/total) | P value* |
|------------------------------|----------------------------|------------------------------|----------|
| Cytoplasm                    | 3/23                      | 16/24                        | 0.0001   |
| Nucleus and cytoplasm        | 19/23                     | 2/24                         |          |

*Fisher’s exact test.

Figure 1. Immunohistochemical staining of VDR. A,C,D,E) Pterygium; B) normal conjunctiva; F) human prostate. Pterygium showed a moderate to strong immunoreactivity of the epithelial cells, mostly localized in both nucleus and cytoplasm (A), while conjunctival epithelium exhibited mainly a mild to moderate cytoplasmic staining (B). In pterygium, the nuclear staining was always stronger than the cytoplasmic. A marked VDR immunoreaction was also detected in epithelial goblet cells (A) (arrows) and in the endothelial cells of sub-epithelial microvessels (A,C) (arrowheads). Scattered immunoreactive leucocytes-like cells, morphologically recognizable as cells belonging to the “mononuclear phagocyte system (MPS)”, were found in the subepithelial connective tissue (C) and inside the vessels (D) (asterisks). Negative (E) and positive (F) control sections. Scale bars: 20 µm.
ciency and the pathogenesis of pterygium. However, in a recent paper, Jee et al. demonstrated a positive association between blood 25(OH)D level and Korean pterygium, but the exact mechanism is unknown. Such discrepancy with the results of our study may be related to the great number of samples they examined, but also to the above-mentioned Sardinian genetic peculiarity. Probably in Sardinia the high insolation rate, on one side, may be an important etiopathogenetic factor for the occurrence of pterygium, which is characterized by chronic inflammation, angiogenesis and uncontrolled proliferation; on the other side, UV rays may not be able to stimulate the production of adequate vitamin D amount in Sardinians, that would be insufficient to exert its protective action against the harmful effects of UV rays on conjunctiva.

Since the action of vitamin D is mediated by the nuclear VDR, expressed by normal and neoplastic cell, we examined VDR expression in biopsic samples of pterygium and normal conjunctiva. In our study, most pterygium samples (19/24, 83%) showed a moderate to strong VDR immunoreactivity, localized in both nucleus and cytoplasm of epithelial cells; nuclear staining was always more intense than the cytoplasmic. Among the normal conjunctival samples, epithelial cells exhibited mainly a mild to moderate cytoplasmic staining for VDR (16/24, 67%). Then, regardless of vitamin D status, similar in both groups of patients, significant differences between VDR immunolocalization in pterygium and normal conjunctiva were noticed; such differences may be linked to the different role of activated VDR in cytoplasm and nucleus. The differences in VDR immunolocalization might be explained considering that in normal conjunctiva vitamin D might regulate cell growth, differentiation and apoptosis by a cytoplasmic pathway; in pterygium, VDR nuclear staining may represent an alternative nuclear pathway by which vitamin D might exert its anti-inflammatory and anti-proliferative effects by the regulation of gene expression. But this is just a theory, because the low vitamin D amount, maybe due to genetic factors, could be insufficient to exert its anti-inflammatory action against the effects of UV rays on conjunctiva. It is well-known that vitamin D is an immunomodulator that can reduce the production of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines, thus modifying the innate immune response of the body. Dysregulation of VDR may lead to exaggerated inflammatory responses; maybe defects in vitamin D and VDR pathways could sustain the condition of chronic inflammation typical of pterygium.

Besides to the well-known pro-apoptotic effects, following UV-trauma vitamin D may have also an anti-apoptotic effect resulting in increased cell survival. Then it is quite clear that cell fate may depend on cellular context, which can be able to address VDR pathway. These considerations would be in agreement with a previous study by Tan et al., who classify pterygium as an UV-related benign condition in which the uncontrolled proliferation is the result of a disorder of apoptosis occurring in conjunctiva; it would also support the results of previous papers, which propose that in pterygium the concomitant overexpression of survivin, an anti-apoptotic protein, and functional loss of p53 might be the basis for an aberrant inhibition of apoptosis.

Moreover, in our pterygium samples, a marked VDR immunostaining was also detected in the endothelial cells of subepithelial microvessels, probably because of the role of calcitriol in the regulation of endothelial cell proliferation and differentiation. Scattered immunoreactive leukocyte-like cells, morphologically recognizable as cells belonging to the “mononuclear phagocyte system (MPS)”, were found in the subepithelial connective tissue of pterygium and inside the vessels, probably because of the role of vitamin D in the regulation of the immune system. In fact, in our previous report we studied the distribution of the immunocompetent cells in pterygium, suggesting that all the effector components of the mucosal immune system, including cells of MPS, are present, and, therefore, demonstrating that an immunopathogenetic mechanism seems to be involved in the pathogenesis of pterygium. Our results on the presence of VDR in leukocyte-like cells are supported by the concept that the induction of VDR by vitamin D occurs in monocytes and, to a lesser degree, in mature macrophages and that vitamin D seems to induce the differentiation of monocytes to macrophages and to enhance the monocyte function in antigen presentation.

Finally, the finding of VDR immunoreactivity in cytoplasm of epithelial goblet cells in both conjunctiva and pterygium is in agreement with the study by Paz et al. on the role of calcium in mucin packaging within conjunctival goblet cells. Then conjunctiva, as skin, may represent an important target tissue for vitamin D, in which it may regulate keratinocytes growth and mucus packaging in goblet cells through the binding to VDR.

References
1. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999;10:282-8.
2. Perra MT, Colombari R, Maxia C, Zucca I, Piras F, Corbu A, et al. Finding of conjunctival melanocytic pigmented lesions within pterygium. Histopathology 2006;48:387-93.
3. Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Di Girolamo N. Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol 2011;178:817-27.
4. Di Girolamo N, McCluskey P, Lloyd A, Coroneo MT, Wakefield D. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci 2000;41:671-9.
5. Perra MT, Maxia C, Zucca I, Piras F, Sirigu P. Immunohistochemical study of human pterygium. Histol Histopathol 2002;17:139-49.
6. Maxia C, Perra MT, Demurtas P, Minerba L, Murtas D, Piras F, et al. Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium. Mol Vis 2009;15:458-63.
7. Demurtas P, Di Girolamo N, Corrias M, Zucca I, Maxia C, Diana A, et al. Immunohistochemical analysis of angiotensin converting enzyme in Sardinian pterygium. Histol Histopathol 2013;28:759-66.
8. Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol 2000;84:212-6.
9. Maxia C, Perra MT, Demurtas P, Minerba L, Murtas D, Piras F, et al. Expression of survivin protein in pterygium and relationship with oxidative DNA damage. J Cell Mol Med 2008;12:2372-80.
10. Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002;43:3430-7.
11. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefe Arch Clin Exp Ophthalmol 1998;236:702-8.
12. Ribatti D, Nico B, Maxia C, Longo V, Murtas D, Mangieri D, et al. Neovascularization and mast cells with tryptase activity increase simultaneous-
25. Dushku N, Reid TW. P53 expression in human pterygium. J Cell Mol Med 2007;11:585-9.

24. Reisman D, McFadden JW, Lu G. Loss of heterozygosity and p53 expression in pterygium. Cancer Lett 2004;206:77-83.

23. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997;16:1179-92.

26. Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997;123:404-5.

27. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tsen SG, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium. Mol Vis 2005;11:50-5.

28. Schneider BG, John-Aryankalayil M, Rowsey JJ, Dushku N, Reid TW. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation. Exp Eye Res 2006;82:91-8.

29. Shahriari M, Kerr PE, Slade K, Grant-Kels JE. Vitamin D and the skin. Clin Dermatol 2010;28:663-6.

30. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-231.

31. Munger KL, Levin LJ, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.

32. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-8.

33. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, Garland CF, Giovannucci E. Epidemic influenza and vitamin D. Epidemiol Infect 2006;134:1129-40.

34. van der Mei IA, Ponsonby AL, Dwyer TF, Blizard L, Simmons R, Taylor BV, et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: case-control study. Br Med J 2003;327:16.

35. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16:83-95.

36. Pilz S, Tomaszewicz A, Obermayer-Pietsch B, Dobnig H, Pieler TR. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 2009;29:3699-704.

37. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227-31.

38. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: Eight year prospective study. Lancet 1989;2:1176-8.

39. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-7.

40. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuomimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.

41. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997;94:9831-5.

42. Srinivasan M, Parwani AW, Hershberger PA, Lenzer DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol 2011;123:30-6.

43. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004;18:2660-71.

44. Dostal LA, Toverud SU. Effect of vitamin D3 on duodenal calcium absorption in vivo during early development. Am J Physiol 1984;246:G528-34.

45. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alloppecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-6.

46. DiaSorin Inc. 2012. LIAISON® 25 OH Vitamin D TOTAL Assay. Available from: https://www.accessdata.fda.gov/ cdrh_docs/pdf11/K112725.pdf

47. Wang Y, Becklund BR, DeLuca HF. Identification of a highly specific and versatile vitamin D receptor antibody. Arch Biochem Biophys 2010;494:166-77.

48. Zhou Z, Xia Y, Bandla S, Zakharov V, Wu S, Peters J, et al. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference. Hum Pathol 2014;45:1744-51.

49. Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 2008;29:361-8.

50. van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011;25:671-80.

51. Demurtas P, Orrù G, Coni P, Minerba L, Corrias M, Sirigu P, et al. Association between the ACE insertion/deletion
polymorphism and pterygium in Sardinian patients: a population based case-control study. BMJ Open 2014;4:e005627.

52. Moral P, Memmi M, Varesi L, Mameli GE, Succa V, Gutierrez B, et al. Study on the variability of seven genetic serum protein markers in Corsica (France). Anthropol Anz 1996;54:97-107.

53. Calò CM, Melis A, Vona G, Piras IS. Sardinian population (Italy): a genetic review. Int J Mod Anthropol 2008;1:1-121.

54. Jee D, Kim EC, Cho E, Arroyo JG. Positive association between Blood 25-hydroxyvitamin D levels and pterygium after control for sunlight exposure. PLoS One 2016;11:e0157501.

55. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne) 2012;3:58.

56. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.

57. Barsony J, Renyi I, McCoy W. Subcellular distribution of normal and mutant vitamin D receptors in living cells. Studies with a novel fluorescent ligand. J Biol Chem 1997;272:5774-82.

58. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun 2017. pii: S0896-8411(17)30463-8 [Epub ahead of print].

59. Sun J. Vitamin D and mucosal immune function. Curr Opin Gastroenterol 2010;26:591-5.

60. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Muor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010;17:273-85.

61. Xu YY, Zhang LY, Zou DL, Liu ZS, Shang XM, Wu HP, et al. Differential expression and function of survivin during the progress of pterygium. Invest Ophthalmol Vis Sci 2014;55:8480-7.

62. Merke J, Milde P, Lewicka S, Hügel U, Klaus G, Mangelsdorf DJ, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989;83:1903-15.

63. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. Calcium signalling pathways in cancer: potential for anticancer therapeutics. Br J Cancer 2017;117(Suppl 1):S129-36.

64. Chung I, Han G, Seshadi M, Gillard BM, Yu WD, Foster BA, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009;69:967-75.

65. Wang Y, Zhu J, DeLuca HF. Where is the vitamin D receptor? Arch Biochem Biophys 2012;523:123-33.

66. Nagy L, Szanto A, Szatmari I, Széles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev 2012;92:739-89.

67. Kreutz M, Andreesen R, Krause SW, Szabo A, Ritze F, Reichel H. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 1993;82:1300-7.

68. Nakamura K, Takahashi T, Sasaki Y, Tsuyuoka R, Okuno Y, Kurino M, et al. 1,25-dihydroxyvitamin D3 differentiates normal neutrophilic promyelocytes to monocytic/macrophage cells in vitro. Blood 1996;87:2693-701.

69. Paz HB, Tisdale AS, Danjo Y, Spurr-Michaud SJ, Argüeso P, Gipson IK. The role of calcium in mucin packaging within goblet cells. Exp Eye Res 2003;77:69-75.

70. Reichrath J, Reichrath S, Heyne K, Vogt T, Roemer K. Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling. Front Physiol 2014;5:166.